Biogen rolled out its Remicade biosimilar in the U.K., thus becoming the first drugmaker to market two anti-TNF biosims there. But don't expect anyone to pull off a similar feat in the U.S. anytime soon.
It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up, AbbVie has sued Amgen for patent infringement.
NEW ORLEANS--Merck & Co. and Samsung Bioepis won’t be the first to roll out a Lantus biosimilar. But they aim to step up the competition when they do--and new data unveiled Monday back their case for approval.